Finding Intent Signals in B2B Life Sciences Account-Based Marketing

Intent data is one of the most powerful concepts in modern B2B marketing. The idea is straightforward: if you can identify which companies are actively researching a problem your solution solves, you can focus your commercial resources on those accounts at precisely the moment they are most likely to buy. Done well, it transforms prospecting from an exercise in educated guessing into something far more precise. This targeted marketing is a core concept of account-based marketing (ABM.)

The challenge for life science companies is that the intent data infrastructure built to support ABM programs was designed almost entirely for the B2B technology sector. The signals it captures, the databases it monitors, and the models it uses to score account intent are calibrated for software buyers — not for the biotech, pharma, and research institutions that make up the life science market. For organizations in this sector, adopting standard ABM intent tooling without adaptation produces a program that is technically sophisticated but commercially misaligned — surfacing the wrong accounts, missing the right ones, and generating noise rather than intelligence.

This post explains what genuine intent looks like in B2B life sciences, why standard ABM platforms are limited in capturing it, and how to build an intent intelligence approach that reflects the actual dynamics of this market.

What Standard ABM Intent Data Actually Measures

To understand why standard intent tools underperform in life sciences, it helps to understand what they are actually measuring.

The major ABM intent platforms — Bombora, 6Sense, Demandbase, Propensity, and others — build their intent models primarily around two types of signal. The first is keyword-based web activity: elevated volumes of search queries and content consumption around specific topics, detected through publisher networks, content partnerships, and search engine data. When an unusual number of employees at a company are searching for terms associated with your solution category — "clinical data management software," "CRO selection," "bioanalytical outsourcing" — the platform flags that company as showing elevated intent.

The fundamental limitation of keyword-based web activity in the life science sector is the granularity required to isolate meaningful commercial signals. When monitoring broad technical terms—such as specific assay types—the resulting data frequently conflates scientists seeking protocol guidance with stakeholders intending to outsource the work. Consequently, relying on standard keyword models often produces a frustrating mix of missed opportunities and false positives, requiring a level of specificity that most generic platforms are unequipped to handle.

The second type of intent data is behavioral pattern matching: tracking when company employees visit competitor websites, engage with industry analyst reports, or interact with solution-category content in ways that suggest an active evaluation is underway.

These signals are genuinely useful in the B2B technology market, where buyers research solutions primarily through web searches, vendor websites, and analyst coverage before initiating contact. When a team is evaluating a new CRM, they search, they compare, they read G2 reviews, and they visit vendor sites. That behavior is detectable and meaningful.

In life sciences, this behavioral pattern either does not exist in the same form, or when it does, it is a lagging indicator rather than a leading one. A biotech that has already decided to outsource its Phase 2 biomarker program and is now requesting proposals is generating keyword intent signals — but by the time those signals are detectable, the evaluation is likely already underway and the vendor shortlist may already be forming. The most valuable moment to reach that account was weeks or months earlier, when the decision to advance the program was made but the vendor selection process had not yet begun.

Standard ABM tools are not designed to surface that earlier signal. They are designed to detect the behavioral footprint of an active search — which in life sciences arrives too late to provide maximum commercial advantage.

What Genuine Intent Looks Like in Life Sciences

The most predictive intent signals in B2B life sciences are not behavioral patterns detected through web monitoring. They are discoverable events — publicly documented milestones in a company's scientific, clinical, and financial development that predictably precede the formation of a buying group around specific vendor needs.

These events are explicit, time-stamped, and available through public data sources. They do not require inference or probabilistic scoring. When they occur, the commercial implication is usually clear.

Clinical trial registrations and IND filings are among the most valuable signals available. A new ClinicalTrials.gov registration indicates that a specific program has been designed, approved for execution, and is preparing to enroll. An IND submission signals that a company is preparing to advance an asset into first-in-human studies. Both events create immediate and specific purchasing needs: clinical operations support, central laboratory services, bioanalytical and biomarker capabilities, regulatory affairs support, and more. The program is defined, the timeline is beginning, and the buying group is forming. Vendors who identify this signal early and engage the relevant personas before the RFP process begins have a meaningful advantage over those who wait to be invited.

Funding events — Series B, C, and D rounds, IPOs, and significant non-dilutive funding such as BARDA contracts or large NIH grants — are direct predictors of program acceleration and vendor investment. Funding does not just provide capital; it creates organizational pressure to deploy that capital productively and to demonstrate progress against the milestones used to justify the raise. The months following a significant funding event are among the most commercially active periods in a biotech's lifecycle. A company that raised a $120M Series C to advance two assets into Phase 2 is not a prospect to put in a nurture sequence — it is an account to engage immediately and aggressively.

Regulatory milestones compress timelines and create urgency. A Fast Track designation, a Breakthrough Therapy designation, an Orphan Drug designation, or a Priority Review designation all signal that the FDA has recognized the potential significance of an asset and is providing mechanisms to accelerate its development. For vendors serving the clinical development pipeline, these designations are a direct signal that the program in question is being resourced and accelerated — and that the buying group associated with it is likely to make decisions faster than a standard development timeline would suggest.

Pipeline advancement events — a company announcing positive Phase 1 data, a transition from preclinical to IND-enabling studies, or a decision to advance an asset from Phase 2 into a pivotal trial — each carry specific and predictable commercial implications. The services and technologies needed at Phase 2 are different from those needed at Phase 1, and the investment required for a pivotal trial is substantially larger. These transitions create new buying groups, new budget allocations, and new vendor needs that did not exist at the prior stage.

Partnerships, licensing deals, and acquisitions can signal both program advancement and organizational transformation. A licensing deal that brings a new asset into a company's pipeline creates immediate needs around program support infrastructure. An acquisition can introduce new therapeutic capabilities and create demand for the vendor relationships needed to support them. Large co-development partnerships with major pharma often trigger significant investment in outsourced services to support the partnered program.

For academic and government research targets, grant award databases — NIH Reporter, BARDA contract awards, DOD funding announcements — are the equivalent signals. A new R01 award to a research group working in a relevant therapeutic area is a direct indicator of funded research activity and the instrument and reagent purchasing that will follow.

Why a Layered Intelligence Approach Outperforms Single-Source Intent

The strongest life science ABM programs do not rely on a single source of intent intelligence. They layer multiple signal types to create a picture of in-market accounts that is both strategically grounded and behaviorally confirmed.

The foundation layer is the public events described above: clinical trial filings, funding rounds, regulatory designations, pipeline transitions. These signals establish that an account has a documentable reason to be in market. They are captured through dedicated life-science data platforms — clinical trial registries, SEC and regulatory filing databases, pipeline intelligence services, and grant award databases — rather than through standard ABM intent platforms.

The second layer is keyword-based behavioral intent, sourced from standard ABM platforms. While this signal type is less predictive in isolation for life science accounts, it remains useful as a corroborating indicator. An account that has recently filed a new IND and shows elevated web activity around relevant search terms is a stronger signal than either data point alone. When event-driven and behavioral intent converge on the same account, the probability of active buying-cycle engagement is significantly higher.

The third layer is first-party engagement data from your own campaigns: website visits, content downloads, webinar registrations, ad interactions, and email engagement. An account that appears in your event-driven intent data, is showing behavioral intent signals in the broader web environment, and has had multiple individuals engage with your own content is an account where a buying group may already be forming. This is the account that should be at the top of your SDR priority list — not because of probabilistic scoring, but because three distinct types of evidence are pointing in the same direction.

From Intent Signal to Commercial Action

Identifying intent signals is only the first step. The commercial value is realized in how quickly and precisely the organization responds to them.

When a target account generates a meaningful intent signal — a new clinical trial registration, a funding round, a regulatory designation — the ideal commercial response is not to add that account to a generic nurture sequence. It is to elevate that account immediately in an ABM program's tier structure, identify or update the buying committee contact list for that account, ensure that contact-level or persona-level advertising is running to the relevant individuals, and — for the highest-priority accounts — trigger targeted outreach from the BD or SDR team within days rather than weeks.

The speed of response matters more in life sciences than most commercial teams appreciate. Buying groups form, make shortlists, and issue RFPs on timelines driven by their program milestones, not by the vendor's campaign calendar. An organization that identifies the intent signal and engages within the first week of a new clinical trial filing is having a different conversation than one that engages two months later when the RFP has already been issued. The window of maximum commercial advantage is real — and it closes.

This is what separates a life science ABM program built on the right intent intelligence from one built on generic tools: not just better targeting, but the ability to act at the right moment, with the right message, to the right people — before the buying process has already decided who is in the room.

Contact-Level ABM: Targeting the Key Individuals Within Accounts 

Most ABM programs target accounts. The best ABM programs target people.

This distinction sounds subtle, but its commercial implications are significant. Account-level targeting — serving ads to all employees at a specified set of companies — is a meaningful improvement over broadcasting to the open market. But it still leaves a gap between the audience your budget is reaching and the audience that actually matters for a deal. Contact-level ABM closes that gap.

This post explains what contact-level ABM is, why it represents a genuine upgrade in precision over standard account-level targeting, and which tools are enabling it in B2B life sciences today.

The Limitation of Account-Level Targeting

When a standard ABM program runs programmatic display advertising to a target account list, the targeting mechanism works at the domain or IP address level. The platform identifies devices associated with the target company's network and serves ads to them. In practice, this means your ads are being seen by a broad cross-section of that organization — finance staff, HR, IT, facilities, legal — the vast majority of whom have no relevance to your solution.

Even layering in title or function targeting on LinkedIn, which significantly improves precision, is an approximation. Targeting "Senior Directors and above in Clinical Operations at your target account list" will reach a useful audience, but it will also include people adjacent to the buying committee, exclude buying committee members with non-standard titles, and provide no visibility into which specific individuals are engaging.

Therefore, if you know specific people to target at an account, using broad level account targeting is inefficient. You end up with significant ad spend reaching large numbers of people who will never influence a purchasing decision, while the specific individuals who will are reached only intermittently and without the individual-level visibility that would make outreach actionable.

Account-level targeting is not without value — it builds brand familiarity across an organization, which has genuine commercial benefit. But for the highest-priority accounts and personas, it limits the ability to prioritize getting in front of the right people.

What Contact-Level ABM Does Differently

Contact-level ABM operates from a fundamentally different starting point: instead of targeting a domain or an IP range, it targets a curated list of specific, named individuals.

Using email addresses, names, or device ID matching, contact-level ABM platforms serve ads directly to identified individuals — the exact people you have determined are most likely to be members of the buying committee at your target accounts. Your budget in contact-level ABM is spent almost entirely on those specific people, rather than on the broader organizational population.

The precision has two important consequences.

First, efficiency improves dramatically. When your advertising reaches a list of 200 named individuals across 40 target accounts - those most likely to be part of buying groups - every impression has much higher relevance. There is limited waste of the kind built into account-level programmatic targeting.

Second, and more importantly for the commercial team, the engagement data becomes individually actionable. In account-level ABM, you might know that three people at a target biotech have clicked on your ads this month — but you may not know who they are, what their roles are, or whether they may be part of an-market buying group. In contact-level ABM, you know that the VP of Translational Medicine clicked twice, the Clinical Program Director clicked four times and visited the content page, and the Head of Procurement opened the email sequence. That is a buying committee picture, not an account-level signal — and it significantly changes how the sales team is empowered to engage with a target account.

How Contact-Level Targeting Works

Contact-level ABM platforms work by matching the contacts on your list to real, observable individuals as they browse the web. When a contact on your list visits a property within the platform's publisher network, the platform recognizes them — through email address matching, device ID resolution, or identity graph lookups — and serves your ad to that specific person. The matching happens behind the scenes; from the contact's perspective, they simply see a relevant ad while going about their normal browsing behavior.

Because recognition and serving happen at the individual level, the engagement data the platform returns is correspondingly granular. Marketers and SDRs can see, for each specific contact, how many impressions they received, which ads they engaged with, what content they interacted with downstream, and how their engagement has trended over time. That individual-level record is what makes contact-level ABM commercially actionable in a way that account-level targeting cannot match.

The practical implication for the sales team is significant. Instead of receiving a notification that "someone at Acme Biotech has been active this week" and having to investigate who that might be, the SDR receives a ranked list of named individuals — with titles, content histories, and engagement frequencies — that tells them precisely who to call, in what order, and what to reference when they do. The quality of that first outreach conversation improves substantially when it can open with specific relevance rather than a generic pitch.

Contact-level platforms also integrate with CRM and marketing automation systems, meaning engagement signals flow automatically into the tools the commercial team is already using. A contact who crosses a defined engagement threshold can trigger an SDR task, a lead score update, or an account elevation — without requiring manual review of campaign data. The system surfaces the signal; the team acts on it.

Building the Right Contact List: Where the Real Work Happens

Contact-level targeting is only as powerful as the list it operates from. Precision targeting of the wrong people produces precise data about irrelevant engagement. The effort invested in constructing a high-quality contact list is what determines whether a contact-level ABM program generates genuine commercial intelligence or merely impressive-looking metrics.

In life sciences, building that list well requires assembling intelligence from several distinct sources and using each to inform the others.

1. Start with Life-Science-Specific Intent Signals to Identify the Right Accounts

Before identifying specific contacts, the first question is: which accounts are most likely to be in an active buying cycle right now? In life sciences, the answer comes not from keyword-based web intent data — the signal type that general-purpose ABM platforms are built around — but from events that are predictive of near-term purchasing need.

A new clinical trial registration indicates that a specific program is advancing and that buying groups are likely forming around the services and capabilities needed to execute it. An IND filing signals that a program is preparing for first-in-human work, with all the operational and scientific purchasing that entails. A Series C or D funding round almost always precedes acceleration of program investment and vendor engagement. A regulatory designation — Fast Track, Breakthrough Therapy, Orphan Drug — compresses timelines and creates urgent purchasing needs. A new partnership or licensing deal may bring capital and new program activity simultaneously.

These events are publicly available and systematically trackable through clinical trial registries, regulatory submission databases, SEC filings, and life-science-specific pipeline intelligence platforms. Organizations that build their target account lists from these signals — rather than from generic web intent data — are starting from a fundamentally stronger intelligence position. The accounts they target are not just companies that look like good fits on paper; they are companies with a demonstrable, time-stamped reason to be in-market for a relevant solution.

2. Map the Right Personas for Each Account Type

With a target account list grounded in life-science-specific intent, the next step is determining which individuals within those accounts belong on the contact list. This is where persona mapping does its most important work.

A well-constructed persona map for a given ICP segment documents the titles, functions, and seniority levels that typically appear on the buying committee for that type of purchase. It is built from commercial experience — the sales and BD team's accumulated knowledge of who is actually present when deals of a given type get evaluated and closed — and validated against known patterns in the target account type.

The persona map translates directly into search criteria: when using a contact database to find individuals at a target account, you are looking for the specific titles and functions identified in the persona map. A precise persona map produces a precise contact list. A vague one — "senior people in clinical" — produces a list that is too broad to be useful for contact-level targeting.

The persona map should also be differentiated by account type. The buying committee for a large pharma account and the buying committee for a Series B biotech may share some common roles but differ significantly in seniority, organizational structure, and the degree to which functions are centralized or distributed across programs.

3. Use Contact Databases to Find the Named Individuals

With target accounts identified through intent signals and target personas defined through the persona map, the final step in list construction is finding the specific named individuals who hold those roles at those accounts.

B2B contact databases — platforms that aggregate professional profile data including name, title, employer, email address, and seniority level — are the primary tool for this work. For life sciences, databases with strong coverage of the biotech and pharma sectors, regularly refreshed to account for the high rate of organizational change in this industry, are essential. A contact list built from data that is twelve months out of date in an environment where companies routinely restructure, merge, or reduce headcount is a list that will underperform.

The database search takes the persona map as its input and returns a set of matching individuals at each target account. That set is then cross-referenced with CRM contacts — elevating anyone the commercial team has already engaged — and supplemented with prior campaign engagement data and sales team intelligence from conferences and prior business development activity.

The resulting contact list is not a generic prospecting database. It is a curated set of individuals who work at accounts with documented reasons to be in-market, in roles that correspond to the buying committee for your specific solution type. That specificity is what makes contact-level ABM generate the kind of engagement data that actually moves pipeline.

The shift from lead-based marketing to account-based marketing was a meaningful evolution. Instead of chasing individual contacts and hoping the right person would eventually surface, ABM focused commercial resources on a defined set of high-value organizations, and measured success at the account level rather than the lead level.

But account-level thinking alone is not the complete picture. An account is not a buyer. A buying committee is.

The most sophisticated B2B marketing programs have taken a further step: targeting not just accounts, but the specific groups of individuals within those accounts who are collectively responsible for a purchase decision. Understanding who those people are, what each of them needs to see before they will advocate for your solution, and how to reach all of them simultaneously is what separates ABM programs that generate real pipeline from those that generate account-level engagement without commercial traction.

This post explains the buying committee reality in B2B life sciences, how ABM can be used to surface and engage every relevant stakeholder, and how the pattern of engagement across a buying group becomes one of the most valuable signals in the entire commercial program.

Why Targeting Accounts Is Necessary but Not Sufficient

When a B2B life science company runs an ABM campaign targeting a specific biotech account, it typically generates engagement from some individuals at that company. An ad gets clicked. A white paper gets downloaded. A webinar registration comes in. These are positive signals, but on their own they tell an incomplete story.

The critical question is not just whether someone at the account is engaging. It is whether the right people at the account are engaging — and whether enough of them are engaging simultaneously to indicate that a purchase decision is being considered.

In most B2B life science purchases, a single engaged contact is rarely sufficient to move a deal forward. The purchasing process involves multiple stakeholders, each with a distinct perspective and a distinct set of concerns. A scientist who loves your technology cannot unilaterally approve a contract. A procurement manager who sees your pricing as competitive cannot evaluate your technical capabilities. Each member of the buying committee holds a piece of the decision — and failing to engage all of them means the deal can stall or die even when the initial interest is genuine.

This is the gap that committee-level targeting is designed to close.

The Anatomy of a Life Science Buying Committee

Buying committees in B2B life sciences vary by organization size, outsourcing model, and the nature of what is being purchased. But most purchase decisions of meaningful size involve some combination of the following personas:

The Scientific End-User: the researcher, scientist, or clinical specialist who will actually use the solution. This person cares primarily about technical performance, methodological fit, and whether the solution will work for their specific application. Their endorsement is typically a prerequisite for any serious vendor evaluation.

The Program or Project Lead: the Clinical Program Director, Principal Investigator, or Head of Development for the specific program driving the purchasing need. This person cares about timelines, deliverables, and whether the vendor can reliably execute against the program milestones. They often function as the internal champion if the scientific case is strong.

The Procurement or Vendor Management Function: responsible for vendor qualification, contract terms, pricing, and compliance with the organization's purchasing policies. This persona is often invisible in early-stage engagement and becomes critical — and potentially obstructive — later in the process if not engaged proactively.

The Finance or Budget Holder: particularly relevant for larger contracts or early-stage biotechs where capital allocation decisions are made at a senior level. For mid-size and large biotech pharma, the budget approval process may be separated from the technical selection process.

The Legal and Regulatory Function: for purchases with regulatory or IP implications (which is a large proportion of life science vendor relationships), legal and regulatory affairs team members may need to review and approve vendor agreements.

The C-Suite or Senior Leadership: for strategic vendor relationships, preferred provider agreements, or contracts representing a significant portion of the organization's budget, executive-level buy-in is often required. Even when executives are not part of the day-to-day evaluation, their awareness and support is frequently necessary to close a deal.

The practical implication is that a marketing program focused exclusively on the scientific end-user — the most natural audience for technically-oriented content marketing — is engaging only one member of a committee that may include five or more distinct decision-makers. ABM creates the framework to reach all of them.

How ABM Surfaces the Buying Committee

Identifying who is on the buying committee at a specific target account requires both proactive list-building and reactive signal-reading.

Proactive persona mapping starts with your ICP and the buying committee profiles documented for each ICP segment. For a given account, the commercial team uses contact databases and LinkedIn to identify the individuals at that company who hold the titles and roles corresponding to each buying committee persona. These individuals become the named contacts in the contact-level targeting list for that account — the specific people to whom ads will be served, SDR outreach will be directed, and webinar invitations will be sent.

Reactive signal-reading is equally important. Not every buying committee member will be visible in advance. Some are identified only when they begin engaging with campaign content — a new title downloading a gated white paper, a different persona registering for a webinar, an unfamiliar name clicking through from a LinkedIn ad. Each new engagement from a previously unknown contact at a target account is a data point that refines and expands the picture of who the buying committee may include.

Contact-level ABM platforms — Influ2 and Propensity are platforms which enable contact-level targeting and individual-level visibility. Rather than knowing only that someone at a target account engaged, marketers can see precisely which person engaged, with what content, and how many times. When three individuals with different titles — a Biomarker Scientist, a Clinical Program Director, and a Procurement Manager — from the same mid-size biotech all interact with relevant content within a two-week window, this is a strong indication of possible  buying-committee level interest. That account should be elevated immediately in scoring and flagged for targeted sales outreach.

Deploying Content That Speaks to Each Persona

Identifying the buying committee is a key step, and one which is enabled by tailored content. Engaging each member of a buying committee effectively requires content and messaging calibrated to each persona's specific concerns — not a single piece of content served to everyone.

This is where the content matrix becomes an essential planning tool. A content matrix maps each buying committee persona to the content types and messages most likely to resonate with them at each stage of the funnel. What it produces in practice is a set of parallel tracks — each targeting a different member of the committee with content relevant to their role — that together build consensus across the full group.

For the scientific end-user, the most effective content is technically substantive: application notes, analytical validation data, peer-reviewed publications, detailed methodology comparisons. This audience wants to see evidence that the solution works and that the team behind it understands the science.

For the program lead, the relevant content shifts toward execution and outcomes: case studies documenting successful program delivery, data on timelines met and milestones achieved, testimonials from peers who have navigated similar program challenges. They need to be confident that the vendor will deliver.

For procurement and finance, the relevant content addresses risk management, vendor qualification, and commercial terms: quality system documentation, regulatory compliance credentials, contract flexibility, pricing transparency, and reference client information.

For senior leadership, the appropriate content is strategic: thought leadership on sector trends, evidence of the vendor's market position and reputation, and any data that positions the relationship as strategically valuable rather than merely transactional.

Running these parallel content tracks through ABM channels — LinkedIn ads targeted by title, contact-level ads to named individuals, email sequences to CRM contacts — means that every member of the buying committee is receiving relevant, role-specific content. This is how consensus is built before the formal vendor evaluation even begins.

A Content Matrix with Examples of Relevant Content by Persona and Engagement Stage

The Pattern of Engagement Is the Signal

The ultimate value of committee-level targeting in ABM is not just that it reaches more people at a target account. It is that the pattern of who is engaging, with what content, and over what timeframe, becomes a reliable indicator of purchase intent.

A single engaged contact might represent genuine interest — or it might represent a researcher doing background reading with no near-term purchasing intent. But when engagement begins to appear across multiple personas at the same account, spanning scientific, operational, and commercial functions, the probability that a buying group is actively evaluating shifts dramatically. The breadth of engagement is the signal.

This is why committee-level visibility changes the nature of the marketing and sales handoff. Instead of passing individual leads to the SDR team and leaving them to figure out whether a deal opportunity exists, a well-instrumented ABM program hands off a picture of the buying committee: which specific individuals have engaged, with which content, and how their engagement maps to the personas typically present when a deal closes. That intelligence turns a cold outreach sequence into a precisely targeted, contextually informed commercial conversation.

The Bottom Line

Targeting accounts is necessary. Targeting buying committees is what makes ABM commercially productive.

The investment required to get there — persona mapping, contact-level targeting infrastructure, parallel content tracks by persona, and the organizational discipline to act on engagement signals quickly — is not trivial. But it is what separates ABM programs that generate genuine pipeline from those that generate engagement data with no clear path to revenue.

In B2B life sciences, where purchasing decisions involve multiple stakeholders and carry real consequences for the programs that depend on them, the ability to surround the full buying committee with relevant, credible, role-specific content before the evaluation formally begins is one of the most durable competitive advantages available.

‍